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Urinary Incontinence (MUI) and Urge Urinary Incontinence
(UUI) in Germany over 12 months. METHODS: PURE is an
ongoing six-month, pan-European, prospective observational
study to determine direct treatment costs for women with UI.
Analysis includes 2175 German patients (mean age 65.1 years)
with SUI (n = 487), MUI (n = 1457) or UUI (n = 231) symptoms.
Participating investigators are ofﬁce based primary care physi-
cians (n = 110), urologists (n = 185), gynaecologists (n = 100)
and other (n = 4). Resource use data for cost estimation was col-
lected retrospectively including medication, conservative treat-
ment, diagnostic and surgical procedures, incontinence products
and visits to health care providers for 12 months preceding base-
line. Unit costs for 2004 from the perspective of statutory health
insurance (SHI) were used. RESULTS: Average total annual costs
for women with UI ranged from 413.0€ for SUI, 438.0€ for UUI
to 585.2€ for MUI. Costs were primarily attributable to pad
costs for SUI (223.5€), MUI (300.3€) and UUI (235.0€). A total
of 52.4% of pad costs were incurred by SHI, with remaining
costs being paid out-of-pocket. Average drug costs were 47.4€
for SUI, 86.1€ for MUI and 107.2€ for UUI. Patients receiving
UI surgery had average surgical costs of 3326.9€. On average,
26.9% of patients with SUI, 44.0% with MUI and 52.8% with
UUI were treated with UI medication, while 10.3% of patients
with SUI, 16.8% with MUI and 17.5% with UUI were ever
treated with surgery. Pad use ranged from 85%, 87.2% to 89.2%
in SUI, MUI and UUI patients, respectively. CONCLUSION:
Patients with MUI were found to incur the highest costs com-
pared to patients with other UI subtypes. Patients with SUI were
treated with UI medication not indicated for use in SUI. Inci-
dence of previous UI surgery was considerable in this treatment
seeking population.
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OBJECTIVE: Over 75% of individuals with Alzheimer’s disease
(AD) residing in nursing homes have behavioral and psycholog-
ical signs of dementia (BPSD). Quetiapine is an atypical antipsy-
chotic that has demonstrated effectiveness in the treatment of
BPSD. This analysis examines the health economic implications
of treating patients with AD and BPSD with quetiapine at a dose
of 200mg per day. METHODS: A discrete event simulation was
developed to compare treatment of institutionalized AD patients
in the US with quetiapine relative to no pharmacological treat-
ment. The model follows individuals over one year, tracking
changes in BPSD and the resulting inﬂuence on costs. Effective-
ness and treatment persistence estimates are based on a ran-
domized, double-blind trial comparing quetiapine to placebo,
while BPSD related nursing home costs are derived from the
Minnesota Case Mix Research Database and published infor-
mation. Costs in the simulation, which are reported in 2004 US
dollars, include nursing home per diems, physician visits, psy-
chiatric and behavioral services, and treatment with quetiapine.
The primary effectiveness outcome is time without clinically sig-
niﬁcant BPSD. RESULTS: Untreated patients incur costs averag-
ing $49,350 per year, clinically signiﬁcant BPSD apparent 87%
of the time. Treatment with quetiapine costs $1142 per year, but
this is entirely offset in savings from other areas, resulting in net
savings of $44 per year. At the same time, patients spend seven
fewer weeks with clinically signiﬁcant BPSD. In repeated simu-
lations, quetiapine dominated no treatment in almost 60% of
replications. In 94% of replications, quetiapine was either dom-
inant or led to incremental costs per BPSD year avoided of under
$5000. Sensitivity analyses showed that variations in BPSD-
speciﬁc nursing home costs had the strongest impact on out-
comes. CONCLUSIONS: These analyses indicate that quetiap-
ine in patients with AD and BPSD is cost-effective and may even
lead to overall health care system savings.
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OBJECTIVE: To assess whether comparable populations can be
created to assess the economic impact of different treatment
strategies for overactive bladder (OAB). METHODS: Data 
were obtained from the PharMetrics Patient-Centric Database 
on patients diagnosed with OAB between January, 2001 and
December, 2002. Patients were stratiﬁed into those receiving a
pharmacological therapy for OAB (ie, long-acting tolterodine,
immediate- or extended-release oxybutynin) versus medical 
management alone. Patients were matched 1 :1 by the estimated
propensity score for OAB pharmacotherapy. A logistic regression
model included selected demographic and clinical characteristics.
A ﬁtted probability of receipt of OAB medication was generated
for all patients, and matching was performed based on a differ-
ence of ± 0.01 in this probability. Differences in patient charac-
teristics as well as outcomes and costs during follow-up were
assessed using descriptive statistics (chi-squares for proportions,
Wilcoxon rank-sum tests for continuous variables). RESULTS:
A total of 29,992 matched pairs were identiﬁed. Patients aver-
aged 50 years of age, and 75% were women. After matching,
differences in all patient characteristics were nonsigniﬁcant, with
the exception of physician specialty. Both groups had a pre-index
Charlson Comorbidity Index of 0.70. The incidence of urinary
tract infection was higher in the group receiving medical man-
agement alone (27.4% vs. 20.2%, p < 0.0001). Mean (± SD)
OAB-related costs were also signiﬁcantly higher in the medical
management group ($454 ± $2559 vs. $253 ± $1985, p <
0.0001). Pharmacy costs were higher in the drug-treated group,
but total costs (OAB-related and unrelated) were numerically
similar ($8666 ± $22,757 vs. $8674 ± $20,496), suggesting that
high pharmacological costs of treatment are offset by reduction
in other OAB- and infection-related costs. CONCLUSIONS:
Creation of comparable cohorts is feasible, even when treatment
interventions differ substantially. Furthermore, OAB pharma-
cotherapy appears to be cost-neutral in the management of the
condition, and may impart selected clinical beneﬁts.
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OBJECTIVE: Postoperative vomiting (POV) is a distressing com-
plication and its incidence ranges from 34%–90% in children
undergoing strabismus surgery when antiemetics are not ad-
ministered prophylactically. This study compares the economic
beneﬁt of ondansetron versus dimenhydrinate as antiemetics
administered prophylactically in children undergoing strabismus
surgery. METHODS: This study, conducted at Toronto’s Hospi-
